Penumbra Files Definitive Proxy for $14.5B Acquisition by Boston Scientific; Shareholder Vote Set for May 6

summarizeSummary

Penumbra Inc. filed a definitive proxy statement for its acquisition by Boston Scientific Corporation for approximately $14.5 billion, or $374 per share, in a cash and stock transaction, with a shareholder vote scheduled for May 6, 2026.

check_boxKey Events

• Merger Agreement Details

  Penumbra is to be acquired by Boston Scientific for an initial value of $374.00 per share, comprising approximately 73.26% cash and 26.74% stock, subject to proration based on shareholder elections.

• Shareholder Vote Scheduled

  A Special Meeting for Penumbra shareholders is set for May 6, 2026, to approve the Merger Agreement. The Penumbra Board unanimously recommends voting 'FOR' the merger.

• Stock Consideration Value Update

  The value of the stock consideration has decreased to $267.83 per Penumbra share as of March 27, 2026, based on Boston Scientific's closing price, down from $374.00 at the January 14, 2026 announcement.

• Regulatory Review Progress

  The FTC issued a Second Request on March 16, 2026, extending the HSR waiting period. Boston Scientific has committed to litigate and divest assets generating up to $300 million in revenue if required for regulatory approval.

auto_awesomeAnalysis

This definitive proxy statement (DEFM14A) is a critical step in Penumbra's acquisition by Boston Scientific, providing shareholders with the final terms and details for their vote on May 6, 2026. The transaction, valued at approximately $14.5 billion or $374 per share at its January 14, 2026 announcement, represents a substantial premium over Penumbra's current market valuation. While the cash component remains fixed, the value of the stock consideration has significantly decreased to $267.83 per Penumbra share as of March 27, 2026, due to fluctuations in Boston Scientific's stock price. This change is a material development for shareholders considering their election options. The ongoing regulatory review, including a Second Request from the FTC, introduces some uncertainty, but Boston Scientific's commitment to divest assets up to $300 million and a $900 million reverse termination fee for regulatory failure underscore its determination to close the deal. The unanimous board recommendation and CEO's intent to take stock signal strong internal confidence in the merger's strategic benefits.